AJR AJR-based Continuing Ed for Technologists
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Capirci, C.
Right arrow Articles by Mariani, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Capirci, C.
Right arrow Articles by Mariani, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.05.0902
AJR 2006; 187:W202-W208
© American Roentgen Ray Society


Original Research

Long-Term Prognostic Value of 18F-FDG PET in Patients with Locally Advanced Rectal Cancer Previously Treated with Neoadjuvant Radiochemotherapy

Carlo Capirci1, Domenico Rubello2, Franca Chierichetti3, Giorgio Crepaldi4, Stefano Fanti5, Giovanni Mandoliti1, Simonetta Salviato6, Giuseppe Boni7, Lucia Rampin2, Cesare Polico1 and Giuliano Mariani7

1 Radiotherapy Department, S. Maria della Misericordia Hospital, Rovigo, Italy.
2 Nuclear Medicine Service-PET Unit, S. Maria della Misericordia Hospital, Rovigo, Italy.
3 Nuclear Medicine Service-PET Center, Castelfranco Veneto General Hospital, Castelfranco Veneto, Italy.
4 Medical Oncology Department, S. Maria della Misericordia Hospital, Rovigo, Italy.
5 Nuclear Medicine Service-PET Unit, S. Orsola-Malpighi Hospital, University of Bologna Medical School, Bologna, Italy.
6 Health Physics Service, S. Maria della Misericordia Hospital, Rovigo, Italy.
7 Regional Center of Nuclear Medicine, University of Pisa Medical School, Via Roma 67, Pisa, Italy I-56126.

OBJECTIVE. The purpose of this study was to assess the prognostic value of 18F-FDG PET performed at restaging in patients with locally advanced rectal cancer who previously underwent neoadjuvant radiochemotherapy.

SUBJECTS AND METHODS. Eighty-eight patients with histologically proven rectal cancer classified at clinical TNM stages II and III were enrolled. Six weeks after radiochemotherapy completion, all patients were restaged by sonography, CT, MRI, endoscopy, and 18F-FDG PET. Surgery was performed in all patients within 8-9 weeks from completion of radiochemotherapy. Median follow-up after surgery was 38 months (range, 6-66 months).

RESULTS. The 5-year overall survival and disease-free survival were 83% and 73%, respectively. Cox multivariate analysis showed that only two parameters at restaging were independent prognostic predictors of both overall survival and disease-free survival: pathologic stage and, especially, after radiochemotherapy 18F-FDG PET findings. The 5-year overall survival was 91% in patients with a negative PET after radiochemotherapy versus 72% in those with a positive PET (p = 0.024) after radiochemotherapy, whereas disease-free survival was 81% and 62% (p = 0.003) for those with the negative and positive PET findings, respectively. Statistical data were further enhanced when combining the pathologic stage with the 18F-FDG PET results: 95% 5-year overall survival in the PET-negative pathologic stages 0 and I patients versus 70% in PET-positive pathologic stages II-IV patients (p = 0.001), whereas disease-free survival was 93% and 65% (p = 0.0003) for the negative and positive PETs, respectively.

CONCLUSION. In patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy, the combined evaluation of pathologic stage and after-radiochemotherapy 18F-FDG PET at restaging identified a subgroup of patients characterized by good response to radiochemotherapy and a more favorable prognosis. In these patients, a conservative surgical approach might be considered.

Keywords: 18F-FDG • genitourinary tract imaging • PET • radiochemotherapy • rectal cancer


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JNMHome page
L.-F. de Geus-Oei, D. Vriens, H. W.M. van Laarhoven, W. T.A. van der Graaf, and W. J.G. Oyen
Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 43S - 54S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Roentgen Ray Society.